Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. View Full Report With TOC @ http://www.researchmoz.us/hepatitis-c-market-and-forecast-hcv-drugs-clinical-trials-hepatitis-c-pipeline-drugs-sales-and-forecast-worldwide-report.html

1. Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast -
Worldwide
Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012.
Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of
chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the
prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading
cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and
asymptomatic character of the infection, many people are unaware of having it.
As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no
effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by
therapeutics. The increase in the prevalence of the disease and the availability of new first-in-class therapies
with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in
HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled
by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a
formidable challenge to prevention and care.
Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C
Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive assessment of the
fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the
Hepatitis C Drug Market Landscape. This report contains 7 chapters.
A. Hepatitis C Drugs Market & Forecast (Chapter 2) B. Hepatitis C Approved Drugs Sales & Forecast
(Chapter 3) C. Hepatitis C Deals & Acquisitions (Chapter 4) D. Hepatitis C – Pipeline Drugs Clinical
Trials (Drugs in Phase III) (Chapter 5) E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase
II) (Chapter 6) F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3)
1. Pegasys 2. Pegintron 3. Incivek 4. Victrelis
Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5)
1. Simeprevir (TMC 435) (Company: Janssen Pharmaceutical) 2. Faldaprevir (BI 201335) (Company:
Boerhinger Ingelheim) 3. Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb) 4. PEG-Interferon
Lambda (Company: Bristol-Myers Squibb) 5. Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
6. Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb) 7. BI-207127 (Company: Boerhinger
Ingelheim) 8. ABT-450/r (Ritonavir) (Company: Abbott Laboratories) 9. ABT-267 (Company: Abbott
Laboratories) 10. ABT-072/333 (Company: Abbott Laboratories) 11. Alisporivir (Company: Novartis)
Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6)
1. Mericitabine (RG-7128) (Company: Roche) 2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche) 3.
GS-9256 (Company: Gilead Sciences) 4. GS-9451 (Company: Gilead Sciences) 5. MK-5172 (Company:
Merck) 6. Sovaprevir (ACH-1625) (Company: Achillion) 7. IDX-320 (Company: Idenix) 8. MK-8742
(Company: Merck) 9. ACH-3102 (Company: Achillion Pharmaceuticals, Inc) 10. IDX-719 (Company: Idenix)
11. PPI-668 (Company: Presidio Pharmaceuticals) 12. Setrobuvir (ANA-598) (Company: Roche) 13. VX-222
(Company: Vertex Pharmaceuticals) 14. GS-9669 (Company: Gilead Sciences) 15. GS-9190 (Tegobuvir)
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

2. (Company: Gilead Sciences) 16. BMS-791325 (Company: Bristol-Myers Squibb)
Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
1. Simeprevir (TMC 435) 2. Faldaprevir (BI 201335) (Boerhinger Ingelheim) 3. Asunaprevir (BMS-650032)
4. Sofosbuvir (PSI-7977 or GS-7977) 5. Daclatasvir (BMS-790052) 6. ABT-450/r (Ritonavir) 7.
ABT-072/333 8. Alisporivir 9. Mericitabine (RG-7128) 10. Danoprevir (RG7227) 11. GS-9256 12. Setrobuvir
(ANA-598) 13. VX-222 14. GS-9190 (Tegobuvir) 15. BMS-791325
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary
research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources
like search engines, News websites, Government Websites, Trade Journals, White papers, Government
Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and
access to more than 500 paid databases.
table Of Content
1. Executive Summary
2. Hepatitis C Drugs – Market & Forecast
3. Hepatitis C – Approved Drugs Sales & Forecast
3.1 Pegasys Sales And Forecast
3.2 Pegintron Sales And Forecast
3.3 Incivek Sales And Forecast
3.4 Victrelis Sales And Forecast
4. Hepatitis C – Deals & Acquisitions
5. Hepatitis C – Pipeline Drugs Clinical Trials (drugs In Phase Iii)
5.1 Simeprevir (tmc 435) (company: Janssen Pharmaceutical)
5.1.1 Phase I
5.1.2 Phase Ii
5.1.3 Phase Iii
5.2 Faldaprevir (bi 201335) (company: Boerhinger Ingelheim)
5.2.1 Phase I
5.2.2 Phase Ii
5.2.3 Phase Iii
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

3. 5.3 Asunaprevir (bms-650032) (company: Bristol-myers Squibb)
5.3.1 Phase I
5.3.2 Phase Ii
5.3.3 Phase Iii
5.4 Sofosbuvir (psi-7977 Or Gs-7977) (company: Gilead Sciences)
5.4.1 Phase Ii
5.4.2 Phase Iii
5.5 Daclatasvir (bms-790052) (company: Bristol-myers Squibb)
5.5.1 Phase Ii
5.5.2 Phase Iii
5.6 Bi-207127 (company: Boerhinger Ingelheim)
5.6.1 Phase I
5.6.2 Phase Ii
5.6.3 Phase Iii
5.7 Peg-interferon Lambda (company: Bristol-myers Squibb)
5.7.1 Phase I
5.7.2 Phase Iii
5.8 Abt-450/r (ritonavir) (company: Abbott Laboratories)
5.8.1 Phase I
5.8.2 Phase Ii
5.8.3 Phase Iii
5.9 Abt-267 (company: Abbott Laboratories)
5.9.1 Phase Ii
5.9.2 Phase Iii
5.10 Abt-072/333 (company: Abbott Laboratories)
5.10.1 Phase I
5.10.2 Phase Ii
5.10.3 Phase Iii
5.11 Alisporivir (company: Novartis)
5.11.1 Phase Ii
5.11.2 Phase Iii
6. Hepatitis C – Pipeline Drugs Clinical Trials (drugs In Phase Ii)
6.1 Mericitabine (rg-7128) (company: Roche)
6.1.1 Phase Ii
6.2 Danoprevir/r (ritonavir) (rg7227) (company: Roche)
6.2.1 Phase I
6.2.2 Phase Ii
6.3 Gs-9256 (company: Gilead Sciences)
6.3.1 Phase Ii
6.4 Gs-9451 (company: Gilead Sciences)
6.4.1 Phase Ii
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

4. 6.5 Mk-5172 (company: Merck)
6.5.1 Phase I
6.5.2 Phase Ii
6.6 Sovaprevir (ach-1625) (company: Achillion)
6.6.1 Phase Ii
6.7 Idx-320 (company: Idenix)
6.7.1 Phase I
6.8 Mk-8742 (company: Merck)
6.8.1 Phase I
6.8.2 Phase Ii
6.9 Ach-3102 (company: achillion Pharmaceuticals, Inc)
6.9.1 Phase I
6.9.2 Phase Ii
6.10 Idx-719 (company: Idenix)
6.10.1 Phase I
6.10.2 Phase Ii
6.11 Ppi-668 (company: Presidio Pharmaceuticals)
6.11.1 Phase I
6.12 Setrobuvir (ana-598) (company: Roche)
6.12.1 Phase I
6.12.2 Phase Ii
6.13 Vx-222 (company: Vertex Pharmaceuticals)
6.13.1 Phase I
6.13.2 Phase Ii
6.14 Gs-9669 (company: Gilead Sciences )
6.14.1 Phase I
6.14.2 Phase Ii
6.15 Gs-9190 (tegobuvir) (company: Gilead Sciences)
6.15.1 Phase Ii
6.16 Bms-791325 (company: Bristol-myers Squibb)
6.16.1 Phase Ii
7. Hepatitis C - Pipeline Drugs Sales Forecast
7.1 Simeprevir (tmc 435) Sales Forecast
7.2 Faldaprevir (bi 201335) (boerhinger Ingelheim) Sales Forecast
7.3 Asunaprevir (bms-650032) Sales Forecast
7.4 Sofosbuvir (psi-7977 Or Gs-7977) Sales Forecast
7.5 Daclatasvir (bms-790052) Sales Forecast
7.6 Abt-450/r (ritonavir) Sales Forecast
7.7 Abt-072/333 Sales Forecast
7.8 Alisporivir Sales Forecast
7.9 Mericitabine (rg-7128) Sales Forecast
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

5. 7.10 Danoprevir (rg7227) Sales Forecast
7.11 Gs-9256 Sales Forecast
7.12 Setrobuvir (ana-598) Sales Forecast
7.13 Vx-222 Sales Forecast
7.14 Gs-9190 (tegobuvir) Sales Forecast
7.15 Bms-791325 Sales Forecast
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide